Comment from BullFrog AI Inc.
AnonymousSupportBusiness
Summary: BullFrog AI, Inc. strongly supports the proposed pilot program for AI-enabled optimization of early-phase clinical trials. The company argues that integrating advanced AI technologies, such as automated data harmonization and causal inference, can significantly reduce development timelines, minimize patient risk, and improve regulatory decision-making.
BullFrog AI, Inc. appreciates the opportunity to respond to the Food and Drug Administration’s Request for Information on the proposed pilot program for AI-enabled optimization of early-phase clinical trials. We strongly support this pilot program and gladly submit our input in the uploaded file. Our responses are provided with the expectation that strategically integrating advanced AI-enabled technologies can significantly reduce development and clinical trial timelines, minimize patient risk, and improve the quality of early-stage regulatory decision-making.
Sincerely,
Vin Singh
Chairman and CEO
BullFrog AI, Inc.